ResearcherHumboldt-Universität zu BerlinActive in the last 2 years
Pirus Ghadjar
Matched on ORCID iD 0000-0002-2747-165X; OpenAlex author ID A5028333961. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 22
2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper
Papers 4
- 68Ga-labeled fibroblast activation protein inhibitor (FAPI) PET/CT for locally advanced or recurrent pancreatic cancer staging and restaging after chemoradioth… Co-author DOI 10.7150/thno.95329↗
- Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma: The HEAT randomised cl… Co-author DOI 10.1016/j.ejca.2022.12.009↗
- Dual Targeting of the EGFR/HER2 Pathway in Combination with Systemic Chemotherapy in Refractory Pancreatic Cancer-The CONKO-008 Phase I Investigation. Co-author DOI 10.3390/jcm11164905↗
- Dose-escalated radiotherapy for unresectable or locally recurrent pancreatic cancer: Dose volume analysis, toxicity and outcome of 28 consecutive patients. Last author DOI 10.1371/journal.pone.0186341↗
Closest collaborators
The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Uwe Pelzer · 4 shared papers, 2017–2024 · strength 0.50
- Paper 68Ga-labeled fibroblast activation protein inhibitor (FAPI) PET/CT for locally advanced or recurrent pancreatic cancer … DOI 10.7150/thno.95329↗
- Paper Dual Targeting of the EGFR/HER2 Pathway in Combination with Systemic Chemotherapy in Refractory Pancreatic Cancer-The C… DOI 10.3390/jcm11164905↗
- Paper Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ducta… DOI 10.1016/j.ejca.2022.12.009↗
- Christopher Neumann · 2 shared papers, 2022–2024 · strength 0.32
- Paper 68Ga-labeled fibroblast activation protein inhibitor (FAPI) PET/CT for locally advanced or recurrent pancreatic cancer … DOI 10.7150/thno.95329↗
- Paper Dual Targeting of the EGFR/HER2 Pathway in Combination with Systemic Chemotherapy in Refractory Pancreatic Cancer-The C… DOI 10.3390/jcm11164905↗
- Helmut Oettle · 2 shared papers, 2022–2023 · strength 0.25
- Paper Dual Targeting of the EGFR/HER2 Pathway in Combination with Systemic Chemotherapy in Refractory Pancreatic Cancer-The C… DOI 10.3390/jcm11164905↗
- Paper Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ducta… DOI 10.1016/j.ejca.2022.12.009↗
- Sebastian Zschaeck · 2 shared papers, 2017–2024 · strength 0.24
- Paper 68Ga-labeled fibroblast activation protein inhibitor (FAPI) PET/CT for locally advanced or recurrent pancreatic cancer … DOI 10.7150/thno.95329↗
- Paper Dose-escalated radiotherapy for unresectable or locally recurrent pancreatic cancer: Dose volume analysis, toxicity and… DOI 10.1371/journal.pone.0186341↗
- Marianne Sinn · 2 shared papers, 2017–2022 · strength 0.21
- Paper Dual Targeting of the EGFR/HER2 Pathway in Combination with Systemic Chemotherapy in Refractory Pancreatic Cancer-The C… DOI 10.3390/jcm11164905↗
- Paper Dose-escalated radiotherapy for unresectable or locally recurrent pancreatic cancer: Dose volume analysis, toxicity and… DOI 10.1371/journal.pone.0186341↗
- Hanno B. Riess · 2 shared papers, 2017–2022 · strength 0.21
- Paper Dual Targeting of the EGFR/HER2 Pathway in Combination with Systemic Chemotherapy in Refractory Pancreatic Cancer-The C… DOI 10.3390/jcm11164905↗
- Paper Dose-escalated radiotherapy for unresectable or locally recurrent pancreatic cancer: Dose volume analysis, toxicity and… DOI 10.1371/journal.pone.0186341↗
- Marcus Bahra · 2 shared papers, 2017–2023 · strength 0.18
- Paper Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ducta… DOI 10.1016/j.ejca.2022.12.009↗
- Paper Dose-escalated radiotherapy for unresectable or locally recurrent pancreatic cancer: Dose volume analysis, toxicity and… DOI 10.1371/journal.pone.0186341↗
- Giulia Metzger · 1 shared paper, 2024 · strength 0.18
- Jens Stieler · 1 shared paper, 2022 · strength 0.14
- Jana Käthe Striefler · 1 shared paper, 2022 · strength 0.14
- Thomas Malinka · 1 shared paper, 2022 · strength 0.14
- Katharina Tschoep · 1 shared paper, 2023 · strength 0.11
- Wolfgang Erwin Thasler · 1 shared paper, 2023 · strength 0.11
- Rainer Fietkau · 1 shared paper, 2023 · strength 0.11
- Rolf Dieter Issels · 1 shared paper, 2023 · strength 0.11
- Lucjan Stanislaw Wyrwicz · 1 shared paper, 2023 · strength 0.11
- Wolfram Trudo Knoefel · 1 shared paper, 2023 · strength 0.11
- Volker Heinemann · 1 shared paper, 2023 · strength 0.11
- Jens Werner · 1 shared paper, 2023 · strength 0.11
- Stefan Hubert Boeck · 1 shared paper, 2023 · strength 0.11
- Christiane J. Bruns · 1 shared paper, 2023 · strength 0.11
- Fritz Klein · 1 shared paper, 2017 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.